---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027672"
form_type: "8-K"
ticker: "ETON"
cik: "0001710340"
company_name: "Eton Pharmaceuticals, Inc."
filed_at: "2026-08-13T20:10:53+00:00"
generated_at: "2026-08-13T20:12:15.591008+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Eton Q2 revenue $37.6M (+99% YoY), raises FY26 guidance to >$145M

## Summary
- Q2 net revenue $37.6M vs $18.9M YoY; GAAP EPS $0.35, non-GAAP $0.43.
- Adjusted EBITDA $16.2M (43% margin) vs $3.1M (16%) YoY; EBITDA $14.1M.
- FY26 revenue guidance raised to >$145M (from >$120M); Adjusted EBITDA margin ≥35% (from ≥30%).
- HEMANGEOL relaunch May 1; ~95% patient conversion by end of June; ASN-001 licensed.
- Acquired U.S. rights to IMPAVIDO (launch Sept 2026); KHINDIVI PAS submitted for expanded indication.

## SEC filing metadata
- accession: 0001437749-26-027672
- form_type: 8-K
- ticker: ETON
- cik: 0001710340
- company_name: Eton Pharmaceuticals, Inc.
- filed_at: 2026-08-13T20:10:53+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/0001437749-26-027672-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710340/000143774926027672/eton20260608_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027672
- JSON: https://secwatch.observer/filing/0001437749-26-027672.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027672.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.